1 The EIC Accelerator Project

The EIC Accelerator Program

The European Innovation Council (EIC) Accelerator program is a key component of the EIC, designed to support small and medium-sized enterprises (SMEs) and startups with high-risk, high-impact innovations. The program is particularly focused on deep-tech initiatives, empowering these companies to scale up and achieve market success. The EIC Accelerator provides financial support through a blended funding model that includes both grants and equity investments, making it a unique offering within the European funding landscape.

Funding Structure

The EIC Accelerator offers a substantial grant of up to €2.5 million, which can be utilized for several purposes, including research and development, prototyping, and commercialization of innovative products or services. This grant is aimed at covering early-stage development costs, thereby reducing the financial burden on startups as they navigate the complexities of bringing their innovations to market.

In addition to grants, the EIC Accelerator provides equity financing. Until 2024, this equity investment can amount to up to €15 million, while starting in 2025, it will be capped at €10 million. This dual funding approach encourages companies to leverage both public and private sector investments, fostering a collaborative ecosystem that enhances the capacity for growth and innovation.

Purpose and Impact

The EIC Accelerator is designed to address the funding gap that often exists for deep-tech startups, which face significant challenges in securing financing due to the high risks and long development timelines associated with their innovations. By offering a combination of grants and equity, the EIC Accelerator aims to stimulate entrepreneurial growth, enhance Europe's competitiveness in the global market, and support the development of groundbreaking technologies.

The program serves not only as a financial resource but also as a strategic partner, offering mentorship, networking opportunities, and access to a wider pool of investors. This holistic support framework helps companies scale effectively and attract further investment from private sectors, thereby contributing to job creation and economic growth across Europe.

EIC Accelerator Winner: ReActive Robotics GmbH

Project Acronym: VEMOtion
Website: reactive-robotics.com/home/
Country: Germany
Submission Date: June 15, 2022

Overview of ReActive Robotics and VEMOtion

ReActive Robotics GmbH is a pioneering company in the field of assistive medical robotics, specifically focusing on enhancing the mobility of critical care patients. The VEMOtion project aims to develop an innovative robotic solution that facilitates very early mobilization (VEM) of patients in intensive care settings. Early mobilization has been shown to significantly improve recovery times and patient outcomes, yet it remains underutilized due to the challenges of patient safety and staff workload.

Technology Basics and Background

The VEMOtion project leverages advanced robotics and AI technologies to create a safe and effective solution for patient mobilization. The core technology involves the development of a robotic exoskeleton that supports patients in performing movement exercises, allowing healthcare providers to assist patients without compromising safety or comfort.

Conclusion

Through the EIC Accelerator program, ReActive Robotics GmbH has secured essential funding to advance the VEMOtion project, positioning itself as a leader in the field of assistive medical robotics. By focusing on early patient mobilization, this initiative not only addresses a significant gap in critical care but also enhances overall patient outcomes, showcasing the transformative potential of technology in healthcare. The EIC Accelerator's support plays a crucial role in empowering companies like ReActive Robotics to innovate and scale, ultimately benefiting the European health system and society at large.

2 The Funding Rounds

# ReActive Robotics GmbH: Funding Journey and Growth

ReActive Robotics GmbH, a Munich-based healthcare startup founded in 2015, has established itself as a pioneer in AI and robot-assisted mobilization technology for hospitals, geriatrics, and nursing care. The company has developed VEMOTION, a globally unique AI-supported robotic assistance system designed for patients, caregivers, therapists, and medical professionals.

Funding Rounds and Financial Growth

ReActive Robotics has successfully secured multiple funding rounds to support its innovative technology development and market expansion: Series A Funding (June 2016) The company received its first major investment in June 2016, securing a seven-digit Series A funding round. This investment was led by MTIP MedTech Innovation Partners AG and included High-Tech Gründerfonds, Bayern Kapital, and TQ-Group. This initial capital enabled the development and clinical validation of several prototypes through 2017.

Second Funding Round Following its Series A success, ReActive Robotics secured a second seven-digit funding round. This round included new lead investor Dr. Doll Holding GmbH along with existing investors MTIP MedTech Innovation Partners AG, High-Tech Gründerfonds, Bayern Kapital, and TQ-Group. These funds were allocated to further market entry in Germany and expansion into other countries.

European Innovation Council (EIC) Funding (2023) In 2023, ReActive Robotics was awarded €2.5 million in funding for its R&D activities by the European Innovation Council. This recognition came after the company submitted its Step 2 proposal on June 15, 2022, and later succeeded in the Step 3 interview.

Latest Funding Round (September 2024) Most recently, in September 2024, ReActive Robotics raised an additional €5 million from investors including Dr. Theo Doll, the TQ Group, Henrik Schunk, Stephan Huber, and the EIC Fund. This funding round represents a significant milestone for the company's growth trajectory and enables further development of its VEMOTION system while supporting national and international market launch efforts.

Total Investment and Valuation

Based on available information, ReActive Robotics has raised a total of approximately $5.57 million (€5 million from the latest round plus previous investments). The company's specific valuation figures are not publicly disclosed in the provided search results.

Investor Information

ReActive Robotics has attracted a diverse group of investors across its funding rounds: Key Investors:

• MTIP MedTech Innovation Partners AG (lead investor in Series A)
• High-Tech Gründerfonds (HTGF) - one of Germany's leading early-stage investors
• Bayern Kapital
• TQ-Group - a leading technology company with robotics expertise
• Dr. Doll Holding GmbH (lead investor in second round)
• Dr. Theo Doll (early-stage investor)
• Henrik Schunk
• Stephan Huber
• EIC Fund

High-Tech Gründerfonds (HTGF), a significant investor in ReActive Robotics, is one of the most active early-stage investors in Germany and Europe, with over 2 billion euros under management across its funds. Since its inception in 2005, HTGF has financed more than 750 startups and successfully sold shares in more than 180 companies.

Company Growth and Achievements

Since its founding in 2015, ReActive Robotics has made significant progress in its mission to improve patient care through robotics:

• The company has successfully developed its VEMOTION system, an AI-supported robotic assistance system
• Critically ill and intensive care patients have received more than 5,000 mobilizations using the company's technology
• The company has established a quality management system and formed partnerships with business suppliers
• ReActive Robotics employs between 11-50 people according to available data

The company continues to pursue its vision of making intelligent robotics the standard of care in a field traditionally dominated by manual therapy, addressing the challenges of demographic change and increasing healthcare costs through innovative automation solutions.

Sources:

• Reactive Robotics: Staying on Course for Growth in the MedTech Sector with a €5 Million investment
• HTGF Investment Reactive Robotics
• Reactive Robotics – Funding, Valuation, Investors, News - Parsers VC
• ReActive Robotics GmbH receives Series A funding
• Reactive Robotics receives second round funding - The Robot Report
• Reactive Robotics Raises €5M in Funding - FinSMEs
• Germany's healthcare startup Reactive Robotics secures €5M

3 The Press Releases

ReActive Robotics GmbH, a company based in Munich, Germany, has been a notable recipient of the European Innovation Council (EIC) Accelerator funding. The company received this funding in June 2022, as part of a highly competitive process where only 75 startups were selected out of over 1,000 applications. This funding is crucial for advancing their innovative medical robotics technology, particularly for early mobilization in intensive care units.

Technology and Products

ReActive Robotics specializes in developing robotic assistance systems for treating intensive care patients. Their technology focuses on automating very early mobilization, which is crucial for improving patient outcomes in critical care settings. The company's products are designed to facilitate early movement rehabilitation following neurological injuries and orthopedic surgeries, particularly gait rehabilitation in neurological patients and recovery from joint replacement procedures.

Funding and Partnerships

The EIC Accelerator funding, which includes grants and equity investments, supports ReActive Robotics in reaching significant milestones in validating their clinical case. This support is part of a broader effort by the European Union to foster deep-tech innovation across the continent. While specific partnerships or collaborations announced since receiving the funding are not detailed, the company's involvement with the EIC Accelerator suggests a strong network within the European innovation ecosystem.

Team Updates

There are no specific team updates or announcements related to ReActive Robotics since the EIC funding. However, the company's success in securing this funding likely reflects a strong team effort, as acknowledged by the company itself.

Patents and Intellectual Property

No recent information on new patents or intellectual property developments by ReActive Robotics is available. However, their technological advancements in medical robotics would typically involve significant intellectual property protection.

Press Releases and Social Media

ReActive Robotics does not appear to have published extensive press releases on their website or social media accounts specifically about the EIC funding or recent developments. However, the company's selection for the EIC funding has been highlighted in various external reports and announcements.

Sources: - Reactive Robotics' EIC Selection

• Success story: Reactive Robotics GmbH
• EIC Accelerator winners and statistics June 2022
• ReActive Robotics company information

4 The Technology Advancements

ReActive Robotics GmbH: Current Capabilities and Advancements

ReActive Robotics GmbH, based in Munich, Germany, specializes in developing adaptive and intelligent therapy robotics designed for the early mobilization of critically ill patients in intensive care units (ICUs). The company's primary product is the VEMOTION system, an AI-driven robotic assistance system that provides early mobilization assistance, aiding in faster recovery and reducing the strain on healthcare workers.

Current Capabilities

• VEMOTION System: This AI-supported robotic assistance system is designed to automate early neurological and orthopedic mobilization for ICU patients. It includes a robotic exoskeleton attached to the patient's bed, allowing for mobilization directly in the bed without the need for manual transfer to separate therapy devices.
• Market Presence: ReActive Robotics operates in Germany, Austria, and the United Kingdom, with plans to expand into the US market. The company has established distribution agreements with major distributors in Austria and Australia.

Advancements Since EIC Accelerator Funding

ReActive Robotics received significant funding in 2022 and subsequent years. By June 2022, the company had already been recognized for its innovative work but did not receive the specific EIC Accelerator funding at that exact date. However, it did receive substantial funding later:

• 2023 EIC Grant: The company was awarded €2.5 million by the European Innovation Council to support research and development activities.
• 2024 Funding: ReActive Robotics secured an additional €5 million to further develop its VEMOTION system and expand its global presence. This funding was led by investors such as Dr. Doll, the TQ Group, Henrik Schunk, Stephan Huber, and the EIC Fund.

Improvements and New Features

The company has continued to enhance its VEMOTION system with integrated AI to better assist caregivers and therapists. This system has been crucial in relieving the burden on healthcare staff and supporting the implementation of positioning therapy guidelines for critically ill patients.

Market Demonstrations and Clinical Trials

ReActive Robotics has successfully mobilized over 5,000 critically ill patients using its VEMOTION system, demonstrating its effectiveness in clinical settings. The technology has been used in hospitals to aid recovery while alleviating strain on healthcare workers.

Patents and Scientific Publications

There are no specific details available on new patents filed or scientific studies published by ReActive Robotics since the EIC funding. However, the company's advancements and funding reflect its commitment to developing innovative solutions for healthcare.

---

Sources: - Reactive Robotics - Products, Competitors, Financials, Employees

• ReActive Robotics GmbH receives Series A funding
• Reactive Robotics Announces €5M to Advance AI-powered Robotic Mobilization in Healthcare
• EIC (European Innovation Council)
• HTGF Investment Reactive Robotics
• ReActive Robotics - About Us

5 The Partnerships and Customers

ReActive Robotics GmbH, a German MedTech company specializing in AI- and robot-assisted mobilization for critical care patients, has established significant partnerships and investor relationships that are shaping its market positioning, technology advancement, and scaling efforts since receiving EIC Accelerator funding in mid-2022.

Partnerships and Investors

Investors as Key Partners:

Reactive Robotics’ recent €5 million funding round was led by prominent investors including Dr. Doll, the TQ Group, Henrik Schunk, Stephan Huber, alongside continued support from the European Innovation Council (EIC) Fund. Earlier in 2023, Reactive Robotics had received a €2.5 million grant from the EIC to boost R&D activities.

Strategic Industrial Partner – TQ Group:

Since early stages (2015), ReActive Robotics has partnered with TQ Group—a leading robotics expertise company—which remains an active investor and strategic partner providing technological know-how crucial for product development and scaling.

MTIP MedTech Innovation Partners AG:

This entity led a Series A funding round along with High-Tech Gründerfonds (HTGF), Bayern Kapital, and TQ Group during earlier financing phases before EIC support. These investors have supported clinical validation efforts critical to product readiness.

Nature of Relationships & Purpose

• The relationships primarily revolve around technology development of their flagship robotic assistance system called VEMOTION®, which uses AI to assist caregivers, therapists, physicians in early mobilization of intensive care patients.
• Investment partners provide capital enabling:
• Continued R&D on AI integration into VEMOTION®,
• Data strategy development,
• Expansion into national and international markets,
• Support for improved patient outcomes while reducing caregiver workload.

Market Positioning Through These Relationships

Reactive Robotics is positioning itself as a pioneer in medical robotic-assisted patient mobilization with strong backing from well-established investors who recognize its innovation potential. The involvement of industrial partners like TQ Group adds credibility regarding robotics expertise.

This combination accelerates their trajectory toward becoming a global leader by enabling scalable production capabilities alongside advanced AI-enabled healthcare solutions addressing:

• Staff shortages,
• Patient recovery efficiency,
• Hospital workflow optimization.

Impact on Technology Advancement & Scaling

The partnerships foster:

• Enhanced technological innovation through access to specialized robotics knowledge (TQ Group),
• Financial resources facilitating accelerated research into AI capabilities within VEMOTION®,
• Strategic guidance supporting international market entry plans,

These factors collectively enable Reactive Robotics to improve its product offering continuously while expanding reach beyond Germany into global healthcare markets.

---

Summary

Since receiving EIC funding after June 15th, 2022:

• Reactive Robotics secured new investments totaling €5 million led by Dr. Doll et al., supplementing previous EIC grants.
• Maintains strategic partnership with TQ Group focused on robotics expertise.
• Collaborates closely with industrial investment firms such as MTIP MedTech Innovation Partners AG and HTGF which back clinical validations.

These collaborations underpin Reactive Robotics’ growth as an innovator in AI-powered robotic mobilization technologies for healthcare settings—helping scale operations internationally while advancing technological sophistication.

---

Sources

6 The Hiring and Company Growth

ReActive Robotics GmbH: Team Growth and Hiring Since EIC Accelerator Funding ReActive Robotics, a Munich-based medical robotics company specializing in AI-driven mobilization systems for intensive care patients, has demonstrated steady growth since securing EIC Accelerator funding in 2022. While exact headcount figures are not publicly disclosed, the company is classified as having 1–25 employees (as of September 2024), with recent hiring likely aligning with its scaling phase.

• Hiring and Team Expansion: The company’s website lists over 20 team members across engineering, clinical operations, and leadership roles. Though specific job postings are not detailed in available sources, their career page emphasizes ongoing recruitment ("WE NEED YOU!") to support product development and market expansion.
• Growth Trajectory: Since its 2015 founding, ReActive Robotics progressed from prototyping to CE-certified commercialization by 2019, with over 5,000 patients treated using its VEMOTION® system as of September 2024. Post-EIC funding growth includes a €5 million raise in September 2024, enabling further AI integration and global outreach.
• Key Leadership Changes: Brigitte Schräetzenstaller-Rauch serves as CEO (as of recent updates), alongside CTO Helfried Peyrl and COO Maximilian Grosse-Dunker. Founding CEO Dr. Alexander König remains associated with the company but no longer appears in current executive listings.
• New Team Roles: Recent hires focus on scaling operations and R&D for the VEMOTION® system. The influx of capital supports roles in AI development, regulatory compliance (notably MDR certification achieved in 2021), and international sales teams to drive adoption beyond Europe.

The combination of expanded leadership expertise and specialized technical talent positions ReActive Robotics to meet rising demand for automated rehabilitation solutions amid healthcare labor shortages. Their emphasis on human-centered robotics aims to establish VEMOTION® as the global standard for early patient mobilization.

---

Sources

• Reactive Robotics | AI Robotic Assistance System
• Reactive Robotics Secures €5M Funding
• About ReActive Robotics

7 The Media Features and Publications

Overview of ReActive Robotics GmbH

ReActive Robotics GmbH is a healthcare startup based in Munich, Germany, dedicated to revolutionizing healthcare through innovative technologies. The company, founded in April 2015, focuses on developing adaptive and intelligent therapy robotics to aid early mobilization for intensive care patients. Their flagship solution, VEMOTION, supports both patients and healthcare professionals in providing early mobilization therapies.

Media Features and Publications

ReActive Robotics has been featured in various media outlets and publications, especially for its innovative approach to healthcare and robotics. In 2024, the company secured €5 million in funding, highlighting its growth potential and recognition in the MedTech sector. Furthermore, they have participated in renowned events like the MEDICA Start-up Competition, where they secured third place with their VEMOTION solution.

Content from Publications

Publications have highlighted ReActive Robotics' commitment to integrating technology with medical expertise to improve patient care and staff efficiency. The company's mission to make intelligent robotics a standard in intensive care has garnered significant attention, especially with their Series A funding and subsequent investments.

Podcasts and Interviews

There is no specific mention of podcasts or interviews featuring the ReActive Robotics team in the available data. However, the company's presence at key industry events suggests their involvement in discussions and presentations related to healthcare innovation.

Conference and Fair Visits

ReActive Robotics has actively participated in significant healthcare conferences. Notably, they showcased live demonstrations at MEDICA, attracting attention from medical specialists and healthcare management leaders. Their participation in the MEDICA Start-up Competition also highlights their engagement in industry events.

Involvement in Events

The company's participation in the MEDICA Start-up Competition and their presence at MEDICA demonstrate their involvement in major healthcare events. These platforms provide opportunities for ReActive Robotics to showcase their innovative solutions and network with industry leaders.

Conclusion

ReActive Robotics GmbH is a pioneering healthcare startup in Germany, focusing on AI- and robot-assisted mobilization solutions. Since receiving EIC Accelerator funding in June 2022, the company has continued to grow and innovate, securing additional investments and participating in key industry events.

Sources: - Reactive Robotics at the MEDICA

• Germany's healthcare startup Reactive Robotics secures €5M
• Reactive Robotics - High-Tech Gründerfonds
• ReActive Robotics-the 11th MEDICA Startup Competition
• ReActive Robotics GmbH receives Series A funding
• HTGF Investment Reactive Robotics